TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14987626
Drug: Subcutaneous needle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous needle insertion
Study: 11669568
Drug: Nursing and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nursing and treatment routines
Study: 9853541
Drug: Wheat bran
Normalized name: Wheat bran
DrugBank: Wheat bran (DB10685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wheat bran supplement (high-fiber control)
Study: 1095283
Drug: Fenmetozole (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenmetozole (100 mg and 200 mg)
Study: 30604197
Drug: Mannuronic acid
Normalized name: mannuronate methylsilanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mannuronic acid (500 mg, two capsules per day orally for 12 weeks)
Study: 29231473
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy group (acupuncture + modified weitong xiaopi formula)
Study: 29231473
Drug: Chinese herbal
Normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese herbal medicine group (modified weitong xiaopi formula)
Study: 29231473
Drug: Western medication
Normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medication group (mosapride citrate capsules)
Study: 23739503
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg of L-carnitine per day
Study: 23739503
Drug: 2000 mg
Normalized name: bran 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2000 mg of L-carnitine per day
Study: 23739503
Drug: Basic therapy
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic therapy only (control group)
Study: 17416110
Drug: Ketamine (n=20):
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (n=20): bolus dose of 0.5 mg x kg(‐1) followed by continuous infusion of 2 microg x kg(‐1) x min(‐1) before surgery.
Study: 9301431
Drug: Intravenous L-arginine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous L-arginine 8 g
Study: 9301431
Drug: Intravenous L-arginine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous L-arginine 30 g
Study: 7019033
Drug: lysozyme chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: lysozyme chloride at doses of 60 to 170 mg/day for 4 to 24 weeks
Study: 20455246
Drug: Pexacerfont 100
Normalized name: Pexacerfont
DrugBank: Pexacerfont (DB12572)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pexacerfont 100 mg/day
Study: 11918753
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (enalapril 10 mg/day and eprosartan 300 mg/day)
Study: 8973851
Drug: epirubicin 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: epirubicin 75 mg/m2
Study: 8973851
Drug: mitozantrone 14
Approvals — FDA: no, EMA: no, PMDA: no
Description: mitozantrone 14 mg/m2
Study: 1333098
Drug: Conjugated estrogens
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated estrogens at 0.625 mg per day
Study: 1333098
Drug: Conjugated estrogens
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated estrogens at 1.25 mg per day
Study: 20214894
Drug: Metformin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin therapy for 3 months
Study: 27690762
Drug: AS03-adjuvanted trivalent
Normalized name: AS03 Adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS03-adjuvanted trivalent inactivated influenza vaccine (AS03-TIV)
Study: 27690762
Drug: Non-adjuvanted trivalent
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-adjuvanted trivalent inactivated influenza vaccine (TIV)
Study: 27690762
Drug: Statistical model
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statistical model based on A/H3N2 attack rates and HI antibody titers
Study: 11095321
Drug: Rabeprazole 10
Normalized name: RABEprazole 10 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole 10 mg once daily
Study: 25100080
Drug: Rabeprazole 5
Normalized name: RABEprazole 5 mg oral delayed release capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole 5 mg once daily
Study: 25100080
Drug: Teprenone 50
Normalized name: teprenone
DrugBank: Teprenone (DB15955)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teprenone 50 mg three times per day (active control)
Study: 22340282
Drug: ALA-PDT (20%
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALA-PDT (20% solution of ALA applied for 1 hour, two sessions)
Study: 22340282
Drug: Imiquimod 5%
Normalized name: Imiquimod 5% Topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imiquimod 5% cream (half a sachet applied twice weekly)
Study: 12000378
Drug: Griseofulvin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Griseofulvin (20 mg x kg(‐1) x day(‐1)) for 12 weeks
Study: 6802779
Drug: Phenobarbital (PB)
Normalized name: Phenobarbital
DrugBank: Phenobarbital (DB01174)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenobarbital (PB) at doses ranging from 0.5 to 1.5 mg/kg/day and from 1.6 to 2.5 mg/kg/day
Study: 6802779
Drug: Low doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low doses of Phenobarbital (PB)
Study: 31642352
Drug: High-dose exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose exercise training (1-hour sessions, 3 times weekly for 12 weeks)
Study: 31642352
Drug: Low-dose exercise
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose exercise training (1-hour sessions, 2 times weekly for 8 weeks)
Study: 23945130
Drug: SP-IPT (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: SP-IPT (25 mg of sulfadoxine and 1.25 mg of pyrimethamine)
Study: 23945130
Drug: Daily co-trimoxazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily co-trimoxazole doses (960 mg per dose)
Study: 16718797
Drug: One-day quadruple
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-day quadruple therapy (omeprazole 20 mg, amoxicillin 1 g, furazolidone 200 mg, colloidal bismuth subcitrate 220 mg four times for one day)
Study: 16718797
Drug: Seven-day triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seven-day triple therapy (omeprazole 40 mg, amoxycillin 1 g, furazolidone 100 mg, all twice a day for 7 days)
Study: 11318078
Drug: 0.5% timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% timolol maleate ophthalmic gel-forming solution (timolol GS) once daily
Study: 9542556
Drug: Epidural tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural tramadol 20 mg
Study: 9542556
Drug: Epidural tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural tramadol 100 mg
Study: 3581680
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of atropine and pilocarpine
Study: 29729169
Drug: Omacor (omega-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omacor (omega-3 polyunsaturated fatty acids) 2 capsules (1680 mg) for one month along with standard treatment
Study: 27566551
Drug: Deep sea
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep sea fish oil (0.2 ml/Kg bodyweight/day)
Study: 27566551
Drug: Corn oil
Normalized name: Corn Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corn oil (0.2 ml/Kg bodyweight/day)
Study: 26599957
Drug: Whole-body vibration
Normalized name: Insects (whole body), mite dermatophagoides farinae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-body vibration (WBV) treatment
Study: 15951544
Drug: Retarded release
Normalized name: diclofenac sodium Extended Release Oral Tablet [Lofensaid Retard]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retarded release phosphatidylcholine (6 g daily for three months)
Study: 7558547
Drug: Preparation of
Normalized name: kit for the preparation of Ga-68
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation of living wills in the treatment group
Study: 7558547
Drug: Preparation of
Normalized name: kit for the preparation of Ga-68
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation of living wills in the control group
Study: 7558547
Drug: Life-sustaining treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Life-sustaining treatment decisions in the treatment group
Study: 7558547
Drug: Life-sustaining treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Life-sustaining treatment decisions in the control group
Study: 2198381
Drug: Cisapride 20
Normalized name: cisapride 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride 20 mg orally
Study: 28101565
Drug: Neuromuscular electrical
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neuromuscular electrical stimulation + conventional physical therapy
Study: 28101565
Drug: Conventional group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional group (sham neuromuscular electrical stimulation + conventional physical therapy)
Study: 20718944
Drug: Δ(9) ‐THC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Δ(9) ‐THC (10 mg in IBS patients, 5 and 10 mg in healthy volunteers)
Study: 17096160
Drug: Hyperfractionation (Hfx)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperfractionation (Hfx) RTx with concurrent TPF CTx
Study: 17096160
Drug: Conventional fractionation
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional fractionation (Cfx) RTx with concurrent TPF CTx
Study: 15190136
Drug: 1.25 mg
Normalized name: menthol 1.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mg of droperidol
Study: 11296071
Drug: Holistic medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Holistic medicine consultations for oncology patients
Study: 11296071
Drug: Holistic medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Holistic medicine consultations for symptom management
Study: 11296071
Drug: Questions about
Approvals — FDA: no, EMA: no, PMDA: no
Description: Questions about specific therapies
Study: 6751374
Drug: Oral beta-carotene
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral beta-carotene
Study: 8157190
Drug: Cisplatin with
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin with 5-FU infusion (regimen B)
Study: 8157190
Drug: Maintenance chemotherapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance chemotherapy with cisplatin
Study: 17408818
Drug: Schwarz subcutaneous
Normalized name: measles virus vaccine live, attenuated Schwarz strain / mumps virus vaccine live, Jeryl Lynn strain / rubella virus vaccine live (Wistar RA 27-3 strain) Injection [Priorix]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schwarz subcutaneous
Study: 17408818
Drug: Edmonston-Zagreb subcutaneous
Normalized name: measles virus vaccine live, Enders' attenuated Edmonston strain / mumps virus vaccine live, Jeryl Lynn strain / rubella virus vaccine live (Wistar RA 27-3 strain) / varicella-zoster virus vaccine live (Oka-Merck) strain Injection [ProQuad]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edmonston-Zagreb subcutaneous
Study: 15131566
Drug: Nebulized lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulized lidocaine (4%, 100 mg) 4 times daily for 8 weeks
Study: 15131566
Drug: Placebo (saline)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline) 4 times daily for 8 weeks
Study: 11176555
Drug: Paper-and-pencil questionnaire
Normalized name: paper birch pollen extract
DrugBank: Betula papyrifera pollen (DB10831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paper-and-pencil questionnaire administration
Study: 11176555
Drug: Computer administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Computer administration
Study: 3124478
Drug: Vitamin B12
Normalized name: Vitamin B12
DrugBank: Cyanocobalamin Co-57 (DB09385)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin B12 and folic acid treatment for 3 months
Study: 30880747
Drug: NACCRT (Neoadjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: NACCRT (Neoadjuvant Concurrent Chemoradiotherapy)
Study: 28201598
Drug: TransCon GH
Normalized name: FUSION PROTEIN OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG- .BETA.)-(118-145)-PEPTIDE (1-28) WITH HUMAN SOMATOTROPIN (GROWTH HORMONE, GH) (29-219) AND TWO TANDEM COPIES OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG-.BETA.)-(118-145)- PEPTIDE (220-247
Approvals — FDA: no, EMA: no, PMDA: no
Description: TransCon GH (0.14 mg GH/kg/wk)
Study: 28201598
Drug: TransCon GH
Normalized name: FUSION PROTEIN OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG- .BETA.)-(118-145)-PEPTIDE (1-28) WITH HUMAN SOMATOTROPIN (GROWTH HORMONE, GH) (29-219) AND TWO TANDEM COPIES OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG-.BETA.)-(118-145)- PEPTIDE (220-247
Approvals — FDA: no, EMA: no, PMDA: no
Description: TransCon GH (0.21 mg GH/kg/wk)
Study: 28201598
Drug: TransCon GH
Normalized name: FUSION PROTEIN OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG- .BETA.)-(118-145)-PEPTIDE (1-28) WITH HUMAN SOMATOTROPIN (GROWTH HORMONE, GH) (29-219) AND TWO TANDEM COPIES OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG-.BETA.)-(118-145)- PEPTIDE (220-247
Approvals — FDA: no, EMA: no, PMDA: no
Description: TransCon GH (0.30 mg GH/kg/wk)
Study: 28201598
Drug: Genotropin (0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genotropin (0.03 mg GH/kg/d)
Study: 19015206
Drug: Certolizumab pegol
Normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Certolizumab pegol 400 mg every 4 weeks
Study: 16080835
Drug: Carvedilol (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (25 mg bid)
Study: 12034158
Drug: Metoprolol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (50 mg bid)
Study: 11913407
Drug: CE +
Normalized name: Multimineral/Multivitamin Oral Tablet [ACE + Z]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CE + MPA 2.5 mg
Study: 11913407
Drug: CE +
Normalized name: Multimineral/Multivitamin Oral Tablet [ACE + Z]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CE + MPA 5 mg
Study: 11913407
Drug: CE +
Normalized name: Multimineral/Multivitamin Oral Tablet [ACE + Z]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CE + MPA 5 mg (last 14 cycle days)
Study: 11913407
Drug: CE +
Normalized name: Multimineral/Multivitamin Oral Tablet [ACE + Z]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CE + MPA 10 mg (last 14 cycle days)
Study: 15863547
Drug: Placebo (matching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (matching tablets)
Study: 7986853
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (without lipids, all caloric intake from hypertonic glucose solution)
Study: 3142775
Drug: Ritanserin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritanserin (10 mg twice daily for 4 weeks)
Study: 31150711
Drug: Topical ivermectin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ivermectin 1% cream and doxycycline 40-mg modified-release capsules (DMR)
Study: 17785705
Drug: Denosumab (30,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denosumab (30, 120, or 180 mg subcutaneously every 4 weeks; 60 or 180 mg every 12 weeks)
Study: 8638357
Drug: Flutamide 125
Normalized name: flutamide 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flutamide 125 mg twice daily
Study: 8638357
Drug: Flutamide 250
Normalized name: flutamide 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flutamide 250 mg once daily
Study: 8638357
Drug: Flutamide 250
Normalized name: flutamide 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flutamide 250 mg twice daily
Study: 8638357
Drug: Flutamide (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flutamide (all doses)
Study: 1602504
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of 3.5 g ampicillin plus 1 g probenecid
Study: 1602504
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg ampicillin orally four times a day for 10 days
Study: 24799159
Drug: Ketamine group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine group (n = 31) received intravenous ketamine 1 mg/kg before incision, followed by 2 μg/kg/minute infusion for 72 hours plus sufentanil patient‐controlled intravenous analgesia after thoracotomy.
Study: 24799159
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (n = 47) received intravenous 0.9% normal saline and infusion plus sufentanil patient‐controlled intravenous analgesia.
Study: 19080323
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus Endostar
Study: 15767771
Drug: 2% ketoconazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% ketoconazole gel
Study: 15767771
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 2% ketoconazole and 0.05% desonide
Study: 15767771
Drug: 0.05% desonide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% desonide gel
Study: 15767771
Drug: Vehicle (unmedicated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle (unmedicated gel)
Study: 14666761
Drug: Yishen Jianpi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yishen Jianpi Yangxue Tongli Therapy (YJYTT)
Study: 6316420
Drug: 5.0 ng/kg/min
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.0 ng/kg/min PGI2 X Na infusion abruptly terminated
Study: 6316420
Drug: 5.0 ng/kg/min
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.0 ng/kg/min PGI2 X Na infusion tapered off over 12 hrs
Study: 15863468
Drug: Probiotic (1x10(9)Lactobacillus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic (1x10(9)Lactobacillus fermentum VRI‐033 PCC; Probiomics), twice daily for 8 weeks
Study: 15863468
Drug: Placebo, equivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, equivalent volume, twice daily for 8 weeks
Study: 10802909
Drug: Nutrient supplements
Normalized name: Votrient
DrugBank: Pazopanib (DB06589)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Nutrient supplements (B vitamins and minerals) administered semi-blinded for the first year, double-blinded in crossover rotations during the second year, and open-label in the ensuing years.
Study: 10802909
Drug: Nutrient supplements
Normalized name: Votrient
DrugBank: Pazopanib (DB06589)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Nutrient supplements continued for at least 2 additional years after the 1-year double-blind phase.
Study: 10802909
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of nutrient supplements after the 1-year double-blind phase.
Study: 8816620
Drug: Gonadotropin-releasing hormone
Normalized name: Gonadotropin-releasing hormone
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gonadotropin-releasing hormone agonist administered intranasally from day 1 of menstrual cycle
Study: 8816620
Drug: Gonadotropin-releasing hormone
Normalized name: Gonadotropin-releasing hormone
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gonadotropin-releasing hormone agonist administered intranasally from day 21 of menstrual cycle
Study: 1574019
Drug: PVRV (Purified
Approvals — FDA: no, EMA: no, PMDA: no
Description: PVRV (Purified Vero Rabies Vaccine)
Study: 1574019
Drug: HDCV (Human
Approvals — FDA: no, EMA: no, PMDA: no
Description: HDCV (Human Diploid Cell Vaccine)
Study: 3998911
Drug: Holding room
Normalized name: dextromethorphan hydrobromide Oral Lozenge [Hold DM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Holding room treatment
Study: 26267817
Drug: Inactivated triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated triple influenza vaccine (TIV)
Study: 26267817
Drug: Monovalent anti-A(H1N1)pdm09
Normalized name: anti-CD11a
DrugBank: Efalizumab (DB00095)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monovalent anti-A(H1N1)pdm09 vaccine
Study: 17434401
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg raltegravir
Study: 17434401
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg raltegravir
Study: 17434401
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg raltegravir
Study: 16130850
Drug: Short course
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short course of prophylactic antibiotics (administered for < 24 hours)
Study: 7575822
Drug: Glycerin enema
Normalized name: glycerin Enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycerin enema (1 mL of glycerin mixed with 1 mL of warmed normal saline) within 30 minutes after birth and repeated at 12 hours of age
Study: 31563272
Drug: Prolonged intermittent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged intermittent theta burst stimulation (piTBS) monotherapy
Study: 31563272
Drug: Repetitive transcranial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repetitive transcranial magnetic stimulation (rTMS) monotherapy
Study: 28236956
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual plus a financial reward for each depot of medication received (€30 per month if fully compliant)
Study: 26582851
Drug: Pregabalin 150
Normalized name: pregabalin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin 150 mg p.o. before surgery and 75 mg twice daily in hospital and for 7 days after discharge
Study: 21692760
Drug: Sugammadex dosed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex dosed at 2 mg.kg(‐1) based on ideal body weight + 40%
Study: 21692760
Drug: Sugammadex dosed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex dosed at 2 mg.kg(‐1) based on ideal body weight
Study: 21692760
Drug: Sugammadex dosed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex dosed at 2 mg.kg(‐1) based on ideal body weight + 20%
Study: 21692760
Drug: Sugammadex dosed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex dosed at 2 mg.kg(‐1) based on real body weight
Study: 9863092
Drug: Kangke Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kangke Injection (RSF)
Study: 9863092
Drug: Glucose-insulin-potassium chloride
Normalized name: glucose / potassium chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose-insulin-potassium chloride (GIK)